Pioglitazone provides greater long-term glycaemic control than glibenclamide [glyburide] in patients with type 2 diabetes mellitus (T2DM)

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1544, 2006-01, pp. : 18-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of Glimepiride vs Glibenclamide on Ischaemic Heart Disease Risk Factors and Glycaemic Control in Patients with Type 2 Diabetes Mellitus

By Britton M.E.   denver A.E.   Mohamed-Ali V.   Yudkin J.S.  

Clinical Drug Investigation, Vol. 16, Iss. 4, 1998-10 ,pp. : 303-317

Adis International

Access to resources Recommend Favorite

A fixed combination of rosiglitazone plus metformin improves glycaemic control and cardiovascular risk factors in patients with type 2 diabetes mellitus (T2DM)

By  

Inpharma, Vol. 1, Iss. 1546, 2006-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Glycaemic control was markedly improved by pioglitazone in a patient with type 2 diabetes mellitus associated with Charcot-Marie-Tooth disease

By  

Inpharma, Vol. 1, Iss. 1393, 2003-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus

By Rajagopalan R.   Perez A.   Ye Z.   Khan M.   Murray F.T.  

Drugs & Aging, Vol. 21, Iss. 4, 2004-01 ,pp. : 259-271

Adis International

Access to resources Recommend Favorite

LAF 237: improved glycaemic control in type 2 diabetes mellitus

By  

Inpharma, Vol. 1, Iss. 1451, 2004-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite